[Pulmonary hypertension and obesity].
Obesity is a morbid condition with hemodynamic consequences affecting the systemic and pulmonary circulations leading to a risk of pulmonary hypertension. Data in the literature do not argue in favor of a direct relationship between pulmonary hypertension and obesity. These two conditions appear to be two distinct entities, the different co-morbidities observed in obesity favoring pulmonary hypertension. Certain co-morbidities, for instance use of anorexic agents, exhibit a clear relationship with pulmonary hypertension. There is also a possible relationship with left ventricular failure, hypoxemia, and other respiratory disorders (including obstructive sleep apnea), hypothyroidism, and thomboembolism.
Sztrymf
B
B
Service de Pneumologie et Réanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Hôpital Antoine-Béclère (AP-HP), Université Paris-Sud, 157, rue de la Porte-de-Trivaux, 92140 Clamart.
Ioos
V
V
Sitbon
O
O
Parent
F
F
Simonneau
G
G
Humbert
M
M
D000635:Aminorex / Q000009:adverse effects / Q000031:analogs & derivatives*; D005277:Fenfluramine / Q000009:adverse effects / Q000031:analogs & derivatives; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology*; D007037:Hypothyroidism / Q000209:etiology; D000860:Hypoxia / Q000209:etiology; D009765:Obesity / Q000150:complications* / Q000503:physiopathology; D012307:Risk Factors; D012720:Severity of Illness Index; D012891:Sleep Apnea Syndromes / Q000209:etiology
D005277:Fenfluramine; D000635:Aminorex; C006559:aminorex fumarate